Published in Cancer Res on June 01, 2008
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (SERPENTINE) | NCT04941365
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res (2012) 2.11
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol (2010) 1.43
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol (2009) 1.40
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest (2009) 1.22
The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol (2013) 1.16
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One (2012) 1.07
Mechanisms and management of doxorubicin cardiotoxicity. Herz (2011) 1.05
Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol (2009) 1.00
FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4. Nat Commun (2013) 0.99
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res (2014) 0.99
High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med (2012) 0.97
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol (2009) 0.95
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) (2011) 0.95
Links between Toll-like receptor 4 and breast cancer. Oncoimmunology (2013) 0.94
Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol (2010) 0.94
Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther (2013) 0.94
Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol (2011) 0.93
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest (2010) 0.92
Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia (2010) 0.92
Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med (2011) 0.89
HMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity. PLoS One (2011) 0.88
HMG modifications and nuclear function. Biochim Biophys Acta (2010) 0.88
Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs (2010) 0.85
Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients. World J Surg Oncol (2013) 0.84
Auxiliary role for D-alanylated wall teichoic acid in Toll-like receptor 2-mediated survival of Staphylococcus aureus in macrophages. Immunology (2009) 0.83
High mobility group box-1 and its clinical value in breast cancer. Onco Targets Ther (2015) 0.83
Sequential metastases of colorectal cancer: Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments. Oncoimmunology (2012) 0.81
Potential association between TLR4 and chitinase 3-like 1 (CHI3L1/YKL-40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer. Curr Mol Med (2013) 0.81
Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget (2016) 0.81
Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med (2013) 0.80
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80
The implication and potential applications of high-mobility group box 1 protein in breast cancer. Ann Transl Med (2016) 0.79
Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resist Updat (2012) 0.78
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we? Eur Arch Otorhinolaryngol (2015) 0.78
Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. Oncoimmunology (2012) 0.78
Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation. J Radiat Res (2015) 0.78
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol (2011) 0.78
Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol (2015) 0.77
An ENU mutagenesis approach to dissect "self"-induced immune responses: Unraveling the genetic footprint of immunosurveillance. Oncoimmunology (2012) 0.77
HMGB1 interacts with XPA to facilitate the processing of DNA interstrand crosslinks in human cells. Nucleic Acids Res (2015) 0.77
Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Cell Stress Chaperones (2013) 0.77
Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy. PLoS One (2015) 0.76
The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles. Immunol Cell Biol (2015) 0.76
Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor. Diagnostics (Basel) (2013) 0.75
Dynamic computational model suggests that cellular citizenship is fundamental for selective tumor apoptosis. PLoS One (2010) 0.75
How to detour Treg cells in T cell-based antitumor immune therapy. Onco Targets Ther (2013) 0.75
A review of the importance of immune responses in luminal B breast cancer. Oncoimmunology (2017) 0.75
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Res Treat (2017) 0.75
Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. Onco Targets Ther (2017) 0.75
Review: the role of hyperthermia in treating pancreatic tumors. Indian J Surg Oncol (2014) 0.75
Impact of Particle Irradiation on the Immune System: From the Clinic to Mars. Front Immunol (2017) 0.75
5-Fluorouracil Induce the Expression of TLR4 on HCT116 Colorectal Cancer Cell Line Expressing Different Variants of TLR4. Iran J Pharm Res (2013) 0.75
Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8(+) T cells. Clin Transl Immunology (2017) 0.75
Standardized pretreatment inflammatory laboratory markers and calculated ratios in patients with oral squamous cell carcinoma. Eur Arch Otorhinolaryngol (2016) 0.75
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47
The hallmarks of aging. Cell (2013) 14.29
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The pathophysiology of mitochondrial cell death. Science (2004) 13.87
Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
Autophagy and aging. Cell (2011) 5.96
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Does autophagy contribute to cell death? Autophagy (2005) 3.21
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61
Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56
Autophagy regulation by p53. Curr Opin Cell Biol (2010) 2.56